Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Noriko Sasase"'
Autor:
Kenji Ando, Soo Ryang Kim, Susumu Imoto, Taisuke Nakajima, Keiji Mita, Katsumi Fukuda, Miyuki Taniguchi, Noriko Sasase, Akira Muramatsu, Toshiyuki Matsuoka, Masatoshi Kudo, Yoshitake Hayashi
Publikováno v:
Case Reports in Gastroenterology, Vol 3, Iss 3, Pp 372-376 (2009)
Acute pancreatitis, an uncommon side effect of pegylated interferon α (PEG-IFN α) and ribavirin (RBV) combination therapy, has rarely been reported in the English language literature. Here, acute pancreatitis associated with PEG-IFN plus RBV treatm
Externí odkaz:
https://doaj.org/article/1b5ef934a3fc43998f773199bacde3ba
Autor:
Soo Ryang Kim, Soo Ki Kim, Hisato Kobayashi, Takako Fujii, Toyokazu Okuda, Atsushi Nakai, Yumi Fujii, Takanobu Hayakumo, Ryuji Suzuki, Aya Otani, Noriko Sasase, Ke-Ih Kim, Tsutomu Kumabe, Yu-ichiro Koma, Osamu Nakashima
Publikováno v:
Kanzo. 64:141-149
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8bc1bb91cb8378801efa3a2c28c9ef3e
https://doi.org/10.2957/kanzo.64.141
https://doi.org/10.2957/kanzo.64.141
Autor:
Soo Ryang Kim, Soo Ki Kim, Takako Fujii, Hisato Kobayashi, Toyokazu Okuda, Takanobu Hayakumo, Atsushi Nakai, Yumi Fujii, Ryuji Suzuki, Noriko Sasase, Aya Otani, Yu-ichiro Koma, Motoko Sasaki, Tsutomu Kumabe, Osamu Nakashima
Publikováno v:
World Journal of Clinical Cases. 11:177-186
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::75747822f43531aebb63452189888dde
https://doi.org/10.12998/wjcc.v11.i1.177
https://doi.org/10.12998/wjcc.v11.i1.177
Autor:
Soo-Ryang Kim, Susumu Imoto, Ikuo Shoji, Yoshi-Hiro Ide, Hak Hotta, Ahmed El-Shamy, Lin Deng, Noriko Sasase
Publikováno v:
Intervirology. 55:1-11
Objective: Hepatitis C virus (HCV genome) polymorphisms are thought to influence the outcome of pegylated-interferon/ribavirin (PEG-IFN/RBV) therapy. This study aimed to examine non-structural protein 5A (NS5A) polymorphisms, e.g. IFN/RBV resistance-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54b2ac1e0a286e679b0f94873c053d3b
https://doi.org/10.1159/000322219
https://doi.org/10.1159/000322219
Autor:
Masanori Sakashita, Yoshiaki Nagata, Akira Nakamura, Masahiko Sugano, Akira Muramatsu, Soo Ryang Kim, Masatoshi Kudo, Susumu Imoto, Tetsuya Makino, Takamitsu Komaki, Takatoshi Nakajima, Erika Konishi, Shinobu Tsuchida, Hiroshi Kasugai, Yutaka Hasegawa, Noriko Sasase, Jun Saito, Kanako Sasatani, Tetsumi Kawada, Aya Fujinami, Ke Ih Kim, Ahmed El-Shamy, Yasuhito Tanaka, Hak Hotta, Teruhisa Morikawa, Noriyo Kimura, Mitsuhiro Ohta
Publikováno v:
Digestion. 84:10-16
Background and Aims: Double-filtration plasmapheresis (DFPP) together with interferon (IFN) administration produces a substantial reduction in the viral load during the early stages of treatment. Methods: Based on their responses to previous pegylate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eaca042ce2a31968879b7e811d62421e
https://doi.org/10.1159/000333209
https://doi.org/10.1159/000333209
Autor:
Miyuki Taniguchi, Keiji Mita, Masatoshi Kudo, Yoshitake Hayashi, Soo Ryang Kim, Akira Muramatsu, Kenji Ando, Taisuke Nakajima, Noriko Sasase, Susumu Imoto, Katsumi Fukuda, Toshiyuki Matsuoka
Publikováno v:
Case Reports in Gastroenterology, Vol 3, Iss 3, Pp 372-376 (2009)
Case Reports in Gastroenterology
Case Reports in Gastroenterology
Acute pancreatitis, an uncommon side effect of pegylated interferon α (PEG-IFN α) and ribavirin (RBV) combination therapy, has rarely been reported in the English language literature. Here, acute pancreatitis associated with PEG-IFN plus RBV treatm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16a0122c65f49f5969d963baf939e3ff
http://www.karger.com/Article/FullText/256557
http://www.karger.com/Article/FullText/256557
Autor:
Ahmed El-Shamy, Hak Hotta, Susumu Imoto, Noriko Sasase, Yoshitake Hayashi, Soo Ryang Kim, Miyuki Taniguchi, Keiji Mita, Akira Muramatsu, Masatoshi Kudo, Satoshi Kitai
Publikováno v:
Digestion. 79:36-39
Recent clinical trials have shown that pegylated interferon-α (PEG-IFN-α) in combination with ribavirin (RBV) improves the rate of sustained virological response (SVR), with over 50% of patients demonstrating a positive response to treatment. Howev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fe8bf455b73d854aafa3e3945ff82df
https://doi.org/10.1159/000203639
https://doi.org/10.1159/000203639
Autor:
Aya Ohtani, Kazuhiko Tanaka, Teruko Hirooka, Noriko Sasase, Yoko Akimoto, Mao Shikata, Ke Ih Kim, Soo Ryang Kim
Publikováno v:
Hepatology International. 2:111-115
Zinc has been reported to ameliorate hematologic side effects and improve liver function. In addition to its various effects, zinc supplementation in chronic hepatitis C patients with genotype 1b of high viral load enhanced the response to interferon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21facecd883740131f2965b1f40eb4d0
https://doi.org/10.1007/s12072-007-9029-y
https://doi.org/10.1007/s12072-007-9029-y
Autor:
Kenji Shimizu, Susumu Imoto, Hirotsugu Ikawa, Toshiyuki Matsuoka, Noriko Sasase, Norifumi Kawada, Soo Ryang Kim, Miyuki Taniguchi, Keiji Mita, Yoshitake Hayashi, Kenji Ando, Masatoshi Kudo
Publikováno v:
Internal Medicine. 47:1899-1903
A case of 22 mm hypervascular nodule in segment two of the liver but without hepatitis B or C virus infection in a 32-year-old Japanese woman with a history of alcohol abuse is presented. Imaging studies such as contrast-enhanced ultrasound, computed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27e55eac272c6a8bf28d2787cdc5fcd9
https://doi.org/10.2169/internalmedicine.47.1221
https://doi.org/10.2169/internalmedicine.47.1221
Autor:
Motoko Nagano-Fujii, Susumu Imoto, Soo Ryang Kim, Mikiko Sasayama, Ahmed El-Shamy, Hak Hotta, Noriko Sasase
Publikováno v:
Scopus-Elsevier
A considerable number of patients infected with Hepatitis C virus subtype 1b (HCV-1b) do not respond to pegylated interferon/ribavirin combination therapy. In this study we explored a useful factor(s) to predict treatment outcome. A total of 47 HCV-1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fe388c5f93a740c2d8fdc7d68a1d62d
https://doi.org/10.1111/j.1348-0421.2007.tb03922.x
https://doi.org/10.1111/j.1348-0421.2007.tb03922.x